Volume 35 Number 8S 180 (135-219) min after methadone intake. QTc did not increase with increasing methadone concentrations, R2 = 0.0015. Conclusion: Another route than renal and hemodialysis must eliminate methadone in these patients as only a small amount of methadone was lost in hemodialysate and urine. All values of serummethadone were comparable with those seen in patients with normal renal function after similar daily methadone doses. QTc tended to increase during hemodialysis. However, this increase was not concentration-dependent on methadone. Introduction: Different pharmaceutical formulations of the cardiovascular drug, calcium antagonist, diltiazem may reflect in its different bioavailability, that may subsequently influence the pharmacological effects. The primary purpose of the study was to compare the cardiovascular activities of 2 different modified-release formulations of diltiazem: gelatine capsules with micropellets and film-coated tablets. Secondary, we would like to consider if the pharmacodynamic data may be useful in concluding the therapeutic equivalence of different diltiazem formulations.
PP207-PharmaCokiNETiCS of SugammadEx 16 mg/kg iN ChiNESE SubjECTS
P.-J. de Kam 1 ; J. Hou 2* ; Z. Wang 3 ; W.H. Lin 1 ; P. Grobara 4 ; and M. van den Heuvel 4 1 Merck Sharp & Dohme Corp., Whitehouse Station, United States; 2 TEDA International Cardiovascular Hospital, Tianjin; 3 MSD, Beijing, China; and 4 MSD, Oss, the Netherlands Introduction: The objectives of this study were to determine the pharmacokinetics (PK) and safety of single-dose sugammadex (16 mg/kg) in healthy Chinese adult volunteers. The 16-mg/kg dose was chosen because this is the highest recommended dose for use in clinical practice, for immediate reversal of NMB.
Patients (or Materials) and Methods:
In this open-label study, healthy Chinese subjects received intravenous (IV) sugammadex (16 mg/kg) as a 10-second bolus infusion. Blood samples were collected pre-sugammadex and at regular intervals up to 24 hours post-sugammadex for PK assessment. Safety was also evaluated, via adverse events (AEs), vital signs, ECG, and laboratory parameters. Results: Twelve subjects were included (6 male; 6 female). Geometric mean (CV%) weight was 58.3 (3.7%) kg and 53.6 (9.8%) kg for males and females, respectively. The main pharmacokinetic parameters are shown in the Table. After the 16-mg/kg sugammadex dose, plasma sugammadex concentrations showed a polyexponential decline over time, indicating 2 to 3 compartments, with an overall geometric mean (CV) terminal half-life (t½) of 145 (17.9%) minutes (139 [17.7%]) minutes for males; 152 [18.6%] minutes for females). No influence of gender on the PK of sugammadex was observed. Three subjects experienced an AE (dysgeusia of mild intensity in all cases), which was considered possibly or probably related to sugammadex. Dysgeusia is a known adverse drug reaction in healthy conscious subjects. There were no clinically significant changes in vital signs, ECG, or laboratory parameters.
Conclusion:
After a single IV bolus infusion dose of sugammadex 16 mg/kg in healthy Chinese subjects, peak sugammadex concentration was 197 μ g/mL, clearance was 99.7 mL/min, and volume of distribution was 10.5 L. No influence of gender on the PK of sugammadex was observed. Overall between-subject variability on clearance and volume of distribution was ~10%. Sugammadex was generally well tolerated in Chinese volunteers. Vss, L 10.3 (7.4%) Vss, L 10.5 (9.0%) a Values given as median (range). T max = time to maximum observed concentration;
C max = maximum observed concentration; CL = clearance, Vss = volume of distribution at equilibrium.
